Hims review

Almost every low-dose option reviewed on this site is a compounded preparation, which means choosing a small dose usually also means accepting a product no regulator has cleared. Hims is the exception worth knowing about: it carries a named microdosing plan on the branded, FDA-approved oral semaglutide. For a reader who wants to hold a small dose and would rather not add the compounding question on top, that combination is genuinely uncommon and it is the reason to look here at all. The wider lineup is broad and openly priced — oral and injectable, both molecules, several branded products with a figure against each, all visible before any intake. What those figures do not do is add up to what you pay. Each one is a starting figure, and each is marked as requiring a membership, with that membership a separate recurring charge rather than something folded into the number on the card. So the published price is the floor of one of two charges. Anyone setting it beside a flat all-in figure from a compounded seller is comparing two different things, and should work out the membership and the medication together before concluding this is the cheaper way to stay small.

Vs median

Not comparable — the published figure is not the whole bill — a membership, platform fee or separate medication charge sits on top of it

Market

$59–$1,300/mo is the full published spread on this site

Structure

Prices the low dose on its own

Consult

Confirm any separate fee

Dietitian

Not confirmed

Labs

Not required

Pricing

Check plan terms

Hims does not sell a compounded product, so no compounding pharmacy is involved. No bloodwork is required before you start. Confirm whether clinician visits cost extra.

Almost every microdose on this site is a compounded preparation. This one is not: Hims attaches a named microdosing plan to the branded, FDA-approved oral semaglutide, which means a reader wanting a small dose can have one without also taking on the compounding question. That combination is genuinely uncommon and it is the reason this row exists. The rest of the lineup is broad and priced openly — oral and injectable, semaglutide and tirzepatide, several branded products with a figure against each, all visible before any intake. What the figures do not do is total up. Each is a "from", each is marked membership required, and the membership is a separate recurring charge rather than something folded into the number on the card. So the published price is the floor of one of two charges, and anybody comparing it against a flat all-in figure elsewhere on this site is comparing different things. Work out the membership and the medication together before deciding this is the cheapest way to hold a small dose.

Every price is a "from" with a separate required membership underneath it.

• The published figure is one of two charges, so it is not the monthly total.
• The cheapest rungs are the oral products; the injectable pens cost substantially more.

Hims is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• Is compounded GLP-1 safe?
• Oral semaglutide (Rybelsus)
• The true annual cost of a plan
• Titration planner